CHELSEA CASTEEL: Open Payments
NPI 1619434172 · WARSAW, MO. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$162 in 8 payments from 7 companies in 2025. Trend: 2023 $278 · 2024 $97 · 2025 $162
Food & beverage: $162
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 2 | $43 |
| Dexcom, Inc. | 1 | $24 |
| Novartis Pharmaceuticals Corporation | 1 | $21 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $20 |
| Lilly USA, LLC | 1 | $20 |
| Novo Nordisk Inc | 1 | $19 |
| AstraZeneca Pharmaceuticals LP | 1 | $15 |
Products named: UBRELVY, Dexcom G6 Transmitter, LEQVIO, CAPLYTA, MOUNJARO, Ozempic, VRAYLAR, AIRSUPRA.
Industry payments across MO — which companies pay providers there.
